title: Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators.
abstract: The purpose of this study was to determine the feasibility, safety, and efficacy of elective stenting with heparin-coated Wiktor stents in patients with coronary artery disease. In experimental studies, heparin coating has been shown to prevent subacute thrombosis and restenosis. Recently, a new method of heparin coating was developed, resulting in a more stable and predictable heparin layer on stent devices. This trial constitutes the first in-human use of this coating procedure, applied on the well-known Wiktor stent device. Heparin-coated Wiktor stent implantation was performed in 132 consecutive patients (132 lesions) in a multicenter international trial from September 1996 to February 1997. Forty-three percent of patients had unstable angina, 33% had previous myocardial infarction, and 10% had diabetes mellitus. Patients were followed for 12 months for occurrence of major adverse cardiovascular events, and 96% of the eligible patients underwent quantitative angiographic control at 6 months. Stent deployment was successful in 95.5% of lesions. Minimal lumen diameter increased by 1.67 +/- 0.48 mm (from 1.02 +/- 0.38 mm before to 2.69 +/- 0.37 mm after the stent implantation). Mean percent diameter stenosis decreased from 67.4 +/- 11.3% before to 18.9 +/- 7.7% after the intervention. A successful intervention (<50% diameter stenosis and no major adverse cardiac events within 30 days) occurred in 97% of the patients. The subacute thrombosis rate was 0.8%, which compares favorably with historical controls of this stent, and a low incidence of postprocedural increase in creatine kinase-MB was noted. At 6 months, event-free survival was 85% and angiographic restenosis rate was 22% with late loss of 0.78 +/- 0.69 mm and a loss index of 0.48 +/- 0.44. Heparin-coated Wiktor stents appeared to be an efficacious device to treat Benestent-like lesions, yielding angiographic and clinical results comparable to a heparin-coated Palmaz-Schatz stent. Despite its use in more complex lesions, the incidence of subacute thrombosis appeared to be lower than historical controls with a similar noncoated stent.
authors.affiliation: AZ St Jan, Genk, Belgium. m.vrolix@ping.be
authors.forename: M C
authors.initials: MC
authors.lastname: Vrolix
authors.forename: V M
authors.initials: VM
authors.lastname: Legrand
authors.forename: J H
authors.initials: JH
authors.lastname: Reiber
authors.forename: G
authors.initials: G
authors.lastname: Grollier
authors.forename: M J
authors.initials: MJ
authors.lastname: Schalij
authors.forename: P
authors.initials: P
authors.lastname: Brunel
authors.forename: L
authors.initials: L
authors.lastname: Martinez-Elbal
authors.forename: M
authors.initials: M
authors.lastname: Gomez-Recio
authors.forename: F W
authors.initials: FW
authors.lastname: Bär
authors.forename: M E
authors.initials: ME
authors.lastname: Bertrand
authors.forename: A
authors.initials: A
authors.lastname: Colombo
authors.forename: J
authors.initials: J
authors.lastname: Brachman
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000628:therapy*; D005240:Feasibility Studies; D005260:Female; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012086:Reoperation; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D020099:Coated Materials, Biocompatible; D006493:Heparin